Research Article
Elevated Serum Fibroblast Growth Factor 21 Is Relevant to Heart Failure Patients with Reduced Ejection Fraction
Table 3
Univariate Cox analysis for prognosis in patients with HFrEF.
| Variables | OR value | value | 95% CI |
| Gender (male, ) | 0.146 | ≤0.001 | 0.061-0.345 | Age (years) | 0.954 | 0.004 | 0.923-9.985 | BMI (kg/m2) | 0.971 | 0.522 | 0.887-1.063 | Hypertension () | 2.489 | 0.007 | 1.286-4.815 | Diabetes mellitus () | 0.602 | 0.154 | 0.300-1.210 | BNP (ng/L) | 1.005 | ≤0.001 | 1.003-1.006 | Creatinine (μmol/L) | 1.003 | 0.002 | 1.001-1.005 | LVEDD (mm) | 0.896 | 0.026 | 0.814-0.987 | LVEF (%) | ≤0.001 | 0.005 | ≤0.001-≤0.001 | FGF21 (pg/mL) | 0.964 | 0.008 | 0.939-0.990 |
|
|
BMI: body mass index; BNP: brain natriuretic peptide; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; FGF21: fibroblast growth factor 21.
|